Radioisotopes in management of metastatic prostate cancer

Amar Raval, Tu D. Dan, Noelle L. Williams, Andrew Pridjian, Robert B. Den

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Metastatic prostate cancer continues to be a leading cause of morbidity and mortality in men with prostate cancer. Over the last decade, the treatment landscape for patients with castrate-resistant disease has drastically changed, with several novel agents demonstrating an improvement in overall survival in large, multi-institutional randomized trials. Traditional treatment with radioisotopes has largely been in the palliative setting. However, the first in class radiopharmaceutical radium-223 has emerged as the only bone-directed treatment option demonstrating an improvement in overall survival. Methods: Medline publications from 1990 to 2016 were searched and reviewed to assess the use of currently approved radioisotopes in the management of prostate cancer including emerging data regarding integration with novel systemic therapies. New positron emission tomography-based radiotracers for advanced molecular imaging of prostate cancer were also queried. Results: Radioisotopes play a crucial role in the diagnosis and treatment of prostate cancer in the definitive and metastatic setting. Molecular imaging of prostate cancer and theranostics are currently being investigated in the clinical arena. Conclusions: The use of modern radioisotopes in selected patients with mCRPC is associated with improvements in overall survival, pain control, and quality of life.

Original languageEnglish (US)
Pages (from-to)277-281
Number of pages5
JournalIndian Journal of Urology
Volume32
Issue number4
DOIs
StatePublished - Oct 1 2016

Fingerprint

Radioisotopes
Prostatic Neoplasms
Molecular Imaging
Survival
Therapeutics
Radium
Radiopharmaceuticals
Positron-Emission Tomography
Publications
Quality of Life
Morbidity
Bone and Bones
Pain
Mortality

Keywords

  • Alpha particle
  • alpharadin
  • bone metastases
  • bone-targeting
  • calcium mimetic
  • metastatic castrate
  • radionuclide
  • radiopharmaceutical
  • radium-223
  • resistant prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Radioisotopes in management of metastatic prostate cancer. / Raval, Amar; Dan, Tu D.; Williams, Noelle L.; Pridjian, Andrew; Den, Robert B.

In: Indian Journal of Urology, Vol. 32, No. 4, 01.10.2016, p. 277-281.

Research output: Contribution to journalArticle

Raval, Amar ; Dan, Tu D. ; Williams, Noelle L. ; Pridjian, Andrew ; Den, Robert B. / Radioisotopes in management of metastatic prostate cancer. In: Indian Journal of Urology. 2016 ; Vol. 32, No. 4. pp. 277-281.
@article{add45886a5604936a660b5d89f391818,
title = "Radioisotopes in management of metastatic prostate cancer",
abstract = "Introduction: Metastatic prostate cancer continues to be a leading cause of morbidity and mortality in men with prostate cancer. Over the last decade, the treatment landscape for patients with castrate-resistant disease has drastically changed, with several novel agents demonstrating an improvement in overall survival in large, multi-institutional randomized trials. Traditional treatment with radioisotopes has largely been in the palliative setting. However, the first in class radiopharmaceutical radium-223 has emerged as the only bone-directed treatment option demonstrating an improvement in overall survival. Methods: Medline publications from 1990 to 2016 were searched and reviewed to assess the use of currently approved radioisotopes in the management of prostate cancer including emerging data regarding integration with novel systemic therapies. New positron emission tomography-based radiotracers for advanced molecular imaging of prostate cancer were also queried. Results: Radioisotopes play a crucial role in the diagnosis and treatment of prostate cancer in the definitive and metastatic setting. Molecular imaging of prostate cancer and theranostics are currently being investigated in the clinical arena. Conclusions: The use of modern radioisotopes in selected patients with mCRPC is associated with improvements in overall survival, pain control, and quality of life.",
keywords = "Alpha particle, alpharadin, bone metastases, bone-targeting, calcium mimetic, metastatic castrate, radionuclide, radiopharmaceutical, radium-223, resistant prostate cancer",
author = "Amar Raval and Dan, {Tu D.} and Williams, {Noelle L.} and Andrew Pridjian and Den, {Robert B.}",
year = "2016",
month = "10",
day = "1",
doi = "10.4103/0970-1591.189708",
language = "English (US)",
volume = "32",
pages = "277--281",
journal = "Indian Journal of Urology",
issn = "0970-1591",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "4",

}

TY - JOUR

T1 - Radioisotopes in management of metastatic prostate cancer

AU - Raval, Amar

AU - Dan, Tu D.

AU - Williams, Noelle L.

AU - Pridjian, Andrew

AU - Den, Robert B.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Introduction: Metastatic prostate cancer continues to be a leading cause of morbidity and mortality in men with prostate cancer. Over the last decade, the treatment landscape for patients with castrate-resistant disease has drastically changed, with several novel agents demonstrating an improvement in overall survival in large, multi-institutional randomized trials. Traditional treatment with radioisotopes has largely been in the palliative setting. However, the first in class radiopharmaceutical radium-223 has emerged as the only bone-directed treatment option demonstrating an improvement in overall survival. Methods: Medline publications from 1990 to 2016 were searched and reviewed to assess the use of currently approved radioisotopes in the management of prostate cancer including emerging data regarding integration with novel systemic therapies. New positron emission tomography-based radiotracers for advanced molecular imaging of prostate cancer were also queried. Results: Radioisotopes play a crucial role in the diagnosis and treatment of prostate cancer in the definitive and metastatic setting. Molecular imaging of prostate cancer and theranostics are currently being investigated in the clinical arena. Conclusions: The use of modern radioisotopes in selected patients with mCRPC is associated with improvements in overall survival, pain control, and quality of life.

AB - Introduction: Metastatic prostate cancer continues to be a leading cause of morbidity and mortality in men with prostate cancer. Over the last decade, the treatment landscape for patients with castrate-resistant disease has drastically changed, with several novel agents demonstrating an improvement in overall survival in large, multi-institutional randomized trials. Traditional treatment with radioisotopes has largely been in the palliative setting. However, the first in class radiopharmaceutical radium-223 has emerged as the only bone-directed treatment option demonstrating an improvement in overall survival. Methods: Medline publications from 1990 to 2016 were searched and reviewed to assess the use of currently approved radioisotopes in the management of prostate cancer including emerging data regarding integration with novel systemic therapies. New positron emission tomography-based radiotracers for advanced molecular imaging of prostate cancer were also queried. Results: Radioisotopes play a crucial role in the diagnosis and treatment of prostate cancer in the definitive and metastatic setting. Molecular imaging of prostate cancer and theranostics are currently being investigated in the clinical arena. Conclusions: The use of modern radioisotopes in selected patients with mCRPC is associated with improvements in overall survival, pain control, and quality of life.

KW - Alpha particle

KW - alpharadin

KW - bone metastases

KW - bone-targeting

KW - calcium mimetic

KW - metastatic castrate

KW - radionuclide

KW - radiopharmaceutical

KW - radium-223

KW - resistant prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84992731149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992731149&partnerID=8YFLogxK

U2 - 10.4103/0970-1591.189708

DO - 10.4103/0970-1591.189708

M3 - Article

VL - 32

SP - 277

EP - 281

JO - Indian Journal of Urology

JF - Indian Journal of Urology

SN - 0970-1591

IS - 4

ER -